EN
登录

ACR 2026:采用新型治疗反应评估指标,达匹罗珠单抗聚乙二醇在系统性红斑狼疮中的治疗反应率高于安慰剂

ACR 2026: Dapirolizumab Pegol Associated with Greater Treatment Response Rates Versus Placebo in SLE Using Novel Treatment Response Measure

优时比 等信源发布 2026-11-09 14:09

可切换为仅中文


BRUSSELS, Belgium and CAMBRIDGE, Mass. — November 9, 2026, 07:00 (CEST) —

比利时布鲁塞尔和美国马萨诸塞州剑桥 — 2026年11月9日,07:00(中欧夏令时)—

UCB (Euronext Brussels: UCB) and Biogen Inc. (Nasdaq: BIIB) today announced further data characterizing the clinical profile of dapirolizumab pegol (DZP), an investigational biologic for people living with systemic lupus erythematosus (SLE). The data are being presented across five posters at ACR Convergence 2026, the annual meeting of the American College of Rheumatology, in Orlando, Florida, November 6-11..

优时比(Euronext Brussels: UCB)与渤健公司(Nasdaq: BIIB)今日公布了进一步表征达匹珠单抗聚乙二醇(DZP)临床特征的数据,该药物是一种用于系统性红斑狼疮(SLE)患者的在研生物制剂。这些数据于11月6日至11日在佛罗里达州奥兰多举行的美国风湿病学会2026年年会(ACR Convergence 2026)上通过五份海报进行展示。

In a post-hoc analysis of the DZP Phase 3 PHOENYCS GO study using the Treatment Response Measure for Systemic Lupus Erythematosus (TRM-SLE), a novel clinical outcome assessment, DZP plus standard of care (SOC) was associated with greater proportions of patients achieving a clinically meaningful response through Week 48 in at least half (TRM-SLE-50) or all (TRM-SLE-100) of their active organ domains, mainly joints and skin, versus placebo plus SOC (Poster 1296)..

在一项针对DZP III期PHOENYCS GO研究的事后分析中,采用了一种新型临床结果评估工具——系统性红斑狼疮治疗反应衡量标准(TRM-SLE)。结果显示,与安慰剂联合标准治疗(SOC)相比,DZP联合标准治疗在48周时使更多患者在至少一半(TRM-SLE-50)或全部(TRM-SLE-100)活动性器官域(主要为关节和皮肤)中达到了具有临床意义的反应(海报1296)。

1

1

“In SLE, patients can improve in ways that matter to them, such as less joint pain or clearer skin, yet fail to register as a treatment responder based on today's trial measures,” said Professor Eric F. Morand, Centre for Inflammatory Diseases, Monash University, Melbourne, Australia, and co-author of the analysis.

“在系统性红斑狼疮(SLE)中,患者可以在对他们重要的方面取得改善,例如关节疼痛减轻或皮肤状况好转,但根据目前的临床试验评估标准,他们可能仍无法被认定为治疗应答者,”澳大利亚墨尔本莫纳什大学炎症性疾病中心教授、该分析的共同作者埃里克·F·莫兰德表示。

“TRM-SLE is designed to provide a simple, patient-centric and clinically intuitive assessment. Applying it to Phase 3 data for the first time is an important step toward a potential future primary outcome measure for clinical studies, one that mirrors how both patients and clinicians judge response.”.

“TRM-SLE 旨在提供一种简单、以患者为中心且具有临床直观性的评估方法。首次将其应用于 III 期数据是迈向未来可能作为临床研究主要终点指标的重要一步,该指标能够反映患者和临床医生对治疗反应的评判方式。”

Difficulty measuring clinically meaningful response to treatment has hindered progress in clinical trials for SLE and impeded the approval of potential new therapies.  To address this, a global taskforce led by Monash University, with clinicians, patient representatives, industry partners and regulatory experts, developed the TRM-SLE as a novel clinical outcome assessment that measures clinically meaningful treatment effects across select organ domains in SLE trials..

难以测量具有临床意义的治疗反应,阻碍了系统性红斑狼疮(SLE)临床试验的进展,并延缓了潜在新疗法的获批。为解决这一问题,由莫纳什大学牵头,联合临床医生、患者代表、行业合作伙伴和监管专家组成的全球工作组开发了TRM-SLE,作为一种新型临床结局评估工具,用于在SLE试验中测量选定器官领域中具有临床意义的治疗效果。

2,3

2,3

In PHOENYCS GO, DZP plus SOC met the primary endpoint of BICLA response at Week 48 versus placebo plus SOC, with results also favoring DZP for SRI-4 response (60% [125/208] vs 41% [44/107]), a secondary outcome not controlled for multiplicity.

在PHOENYCS GO研究中,与安慰剂加标准治疗(SOC)相比,DZP加标准治疗在第48周达到了BICLA应答的主要终点,且SRI-4应答结果也倾向于DZP组(60% [125/208] vs 41% [44/107]),这是一个未对多重性进行控制的次要结局指标。

4

4

In the TRM-SLE analysis, DZP plus SOC through Week 48 was associated with a greater proportion of patients achieving TRM-SLE-50 (61.2% vs 43.2%) and TRM-SLE-100 (52.5% vs 36.8%) compared with placebo plus SOC, representing clinically meaningful improvements in at least half or all of their active organ domains, respectively.

在TRM-SLE分析中,与安慰剂加标准治疗(SOC)相比,地西泮(DZP)加标准治疗至第48周与更高比例的患者达到TRM-SLE-50(61.2% vs 43.2%)和TRM-SLE-100(52.5% vs 36.8%)相关,分别代表至少一半或所有活动性器官域具有临床意义的改善。

At baseline, patients primarily fulfilled the arthritis (joint) and mucocutaneous (skin) TRM-SLE domains..

在基线时,患者主要符合TRM-SLE的关节炎(关节)和皮肤黏膜(皮肤)领域。

1

1

The authors concluded that TRM-SLE distinguished response rates between the treatment arms and offers a potentially practical way to determine response to therapy in patients with SLE, while noting that further validation of the measure is needed.

作者得出结论,TRM-SLE 能够区分各治疗组之间的应答率,并为确定系统性红斑狼疮(SLE)患者对治疗的应答提供了一种潜在实用的方法,同时指出该指标仍需进一步验证。

1

1

TRM-SLE was applied here as a post-hoc analysis rather than as a pre-specified endpoint or as part of any regulatory submission.

TRM-SLE 在此作为事后分析应用,而非作为预先指定的终点或任何监管申报的一部分。

“Progress in SLE depends not only on new medicines, but on how we recognize and measure meaningful outcomes,” said Donatello Crocetta, Chief Medical Officer and Head of Global Medical Affairs at UCB. “UCB and Biogen are pleased to support the taskforce behind TRM-SLE, and applying this framework to our Phase 3 data, alongside our analyses of sustained low disease activity and remission, reflects our commitment to advancing the science of meaningful and sustained treatment outcomes in SLE.

“系统性红斑狼疮(SLE)的进展不仅取决于新药的研发,还取决于我们如何识别和衡量具有临床意义的结局。”UCB首席医疗官兼全球医学事务负责人Donatello Crocetta表示。“UCB和Biogen很高兴支持TRM-SLE背后的工作组,并将该框架应用于我们的III期临床试验数据,结合我们对持续低疾病活动度和缓解的分析,这体现了我们致力于推动SLE领域具有临床意义且持久的治疗结局科学发展的承诺。”

By helping refine how treatment response is evaluated, we hope to support better evidence generation, contribute to evolving standards in SLE trials and, ultimately, better outcomes for people living with this condition.”.

“通过帮助优化治疗反应的评估方式,我们希望支持更高质量的证据生成,推动系统性红斑狼疮(SLE)临床试验标准的不断演进,并最终改善患者的预后。”

Sustaining Low Disease Activity and Remission in Patients with SLE

维持系统性红斑狼疮患者的低疾病活动度和缓解状态

In a separate presentation, post-hoc analyses of PHOENYCS GO examined sustained attainment of low disease activity and remission with DZP plus SOC, endpoints of recognized prognostic importance in SLE. Across the final three study visits (Weeks 40, 44 and 48), greater proportions of patients receiving DZP plus SOC versus placebo plus SOC were found to achieve sustained LLDAS (24.0% [50/208] vs 10.3% [11/107]; nominal p=0.0012), sustained LLDAS-5, which requires a glucocorticoid dose of ≤5 mg/day prednisone equivalent (19.2% [40/208] vs 5.6% [6/107]; nominal p=0.0002), and sustained DORIS (11.5% [24/208] vs 4.7% [5/107]; nominal p=0.0253) (Poster 2196)..

在另一项报告中,对PHOENYCS GO研究进行的事后分析考察了DZP联合标准治疗(SOC)在系统性红斑狼疮(SLE)中具有公认预后重要性的终点指标——持续达到低疾病活动度和缓解方面的表现。在最后三次研究访视(第40、44和48周)期间,与安慰剂联合SOC相比,接受DZP联合SOC治疗的患者中有更高比例实现了持续低疾病活动状态(LLDAS)(24.0% [50/208] vs 10.3% [11/107];名义p=0.0012)、持续LLDAS-5(要求糖皮质激素剂量≤5 mg/天泼尼松等效剂量)(19.2% [40/208] vs 5.6% [6/107];名义p=0.0002)以及持续DORIS缓解(11.5% [24/208] vs 4.7% [5/107];名义p=0.0253)(海报2196)。

5

5

“Our understanding of SLE has evolved, and so must the way we research potential treatments. Following the science means using additional measurement tools to fully understand how our treatments could potentially benefit people living with SLE. We are excited that this first application of TRM-SLE to Phase 3 trial data adds to the evidence reflecting the potential of dapirolizumab pegol.

“我们对系统性红斑狼疮(SLE)的认识不断深化,因此我们研究潜在治疗方法的方式也必须随之演进。遵循科学原则意味着运用额外的测量工具,以全面了解我们的治疗方案可能为SLE患者带来的获益。我们很高兴看到,TRM-SLE在III期临床试验数据中的首次应用,进一步丰富了反映聚乙二醇化达匹罗珠单抗潜力的证据。”

We are committed to deepening our understanding of the disease, advancing the science and ultimately helping improve outcomes for people living with SLE,” said Diana Gallagher, MD, Head of the Immune-Mediated and Neurodegeneration Development Unit at Biogen..

“我们致力于深化对这种疾病的理解,推动科学发展,并最终帮助改善系统性红斑狼疮(SLE)患者的预后。”渤健公司免疫介导疾病与神经退行性疾病研发部门负责人戴安娜·加拉格尔博士表示。

The Phase 3 PHOENYCS GO study was published in

3期PHOENYCS GO研究发表于

The Lancet

《柳叶刀》

in May 2026, reporting statistically significant and clinically meaningful improvement in disease activity with DZP plus SOC versus placebo plus SOC at Week 48, as measured by BICLA response (50% [103/208] vs 35% [37/107]; p=0.011).

在2026年5月,报告称与安慰剂加标准治疗(SOC)相比,DZP加标准治疗在第48周时疾病活动度具有统计学显著性和临床意义的改善,以BICLA反应为衡量指标(50% [103/208] vs 35% [37/107];p=0.011)。

4

4

In the study, DZP showed a generally favorable safety profile, with safety findings consistent with previous DZP studies.

在该研究中,地西泮(DZP)总体表现出良好的安全性,其安全性结果与既往地西泮研究一致。

4,6

4,6

Treatment-emergent adverse events were more common with DZP plus SOC versus placebo plus SOC, while serious treatment-emergent adverse events were less frequent in the DZP plus SOC arm, and discontinuations due to treatment-emergent adverse events were low in both groups.

与安慰剂联合标准治疗(SOC)相比,地西泮(DZP)联合标准治疗的治疗期不良事件更为常见,而严重治疗期不良事件在地西泮联合标准治疗组中较少见,且两组因治疗期不良事件导致的停药率均较低。

4

4

Additional Information

附加信息

TRM-SLE

TRM-SLE

: Treatment Response Measure for Systemic Lupus Erythematosus (TRM-SLE), a novel clinical outcome assessment developed by a global taskforce with regulatory input. It assesses response in each patient's active organ domains, drawn from six: arthritis, mucocutaneous, nephropathy, serositis, hemolytic anemia and thrombocytopenia..

系统性红斑狼疮治疗反应评估指标(TRM-SLE)是一种新型临床结局评估工具,由一个获得监管机构意见输入的全球工作组开发。该工具评估每位患者在活跃受累器官领域的治疗反应,涵盖以下六个领域中的相关部分:关节炎、皮肤黏膜病变、肾病、浆膜炎、溶血性贫血和血小板减少症。

1,3

1,3

TRM-SLE-50/100

TRM-SLE-50/100

: clinically meaningful improvement in at least half (TRM-SLE-50) or all (TRM-SLE-100) of a patient's active TRM-SLE domains.

:患者的活动性TRM-SLE领域中,至少一半(TRM-SLE-50)或全部(TRM-SLE-100)出现具有临床意义的改善。

1

1

BICLA

BICLA

: British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA), the primary endpoint of PHOENYCS GO. A BICLA response requires improvement in all organ systems active at baseline without worsening in others, no worsening in Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K) total score, and no significant deterioration in Physician Global Assessment (PGA)..

基于英国岛屿狼疮评估小组(BILAG)的综合狼疮评估(BICLA),这是PHOENYCS GO研究的主要终点。BICLA反应要求所有在基线时活跃的器官系统均得到改善,其他器官系统无恶化,系统性红斑狼疮疾病活动指数-2000(SLEDAI-2K)总分无恶化,且医师整体评估(PGA)无显著恶化。

4

4

SRI-4

SRI-4

: SLE Responder Index-4 (SRI-4), a composite measure based primarily on improvement in SLEDAI-2K score.4

系统性红斑狼疮应答者指数-4(SRI-4),一种主要基于SLEDAI-2K评分改善的综合评估指标。4

LLDAS / LLDAS-5

LLDAS / LLDAS-5

: Lupus Low Disease Activity State (LLDAS). LLDAS-5 is LLDAS with a glucocorticoid dose of ≤5 mg/day prednisone equivalent.

狼疮低疾病活动状态(LLDAS)。LLDAS-5 是指糖皮质激素剂量≤5 mg/天(以泼尼松等效剂量计)的 LLDAS。

5

5

DORIS

多丽丝

: Definitions of Remission in SLE (DORIS).5

系统性红斑狼疮缓解定义(DORIS)。5

Sustained LLDAS, LLDAS-5 and DORIS

持续性LLDAS、LLDAS-5和DORIS

: achieved at each of the final three study visits (Weeks 40, 44 and 48).

:在末三次研究访视(第40周、第44周和第48周)均实现。

5

5

About Dapirolizumab Pegol

关于达匹罗珠单抗聚乙二醇

Dapirolizumab pegol is a novel investigational humanized Fc-free polyethylene glycol (PEG)-conjugated antigen-binding (Fab’) fragment.

Dapirolizumab pegol 是一种新型在研的人源化、无Fc段、聚乙二醇(PEG)偶联的抗原结合(Fab’)片段。

6

6

Dapirolizumab pegol inhibits CD40L signaling, which has been shown to reduce B-cell activation and autoantibody production, mitigate type 1 interferon (IFN) secretion and attenuate T-cell and antigen-presenting cell (APC) activation.6 Dapirolizumab pegol is presently in Phase 3 clinical development for the treatment of systemic lupus erythematosus (SLE) under a collaboration between UCB and Biogen..

Dapirolizumab pegol 抑制 CD40L 信号传导,已证实可减少 B 细胞活化及自身抗体产生,减轻 I 型干扰素(IFN)分泌,并减弱 T 细胞和抗原呈递细胞(APC)的活化。6 目前,在 UCB 与 Biogen 的合作下,Dapirolizumab pegol 正处于治疗系统性红斑狼疮(SLE)的 III 期临床开发阶段。

7,8

7,8

Dapirolizumab pegol is an investigational biologic currently in clinical development. The safety and efficacy have not been established, and it is not approved by any health authority worldwide.

Dapirolizumab pegol 是一种处于临床研究阶段的在研生物制剂。其安全性和有效性尚未确立,且未获得全球任何卫生监管机构的批准。

About UCB

关于 UCB

UCB is a global biopharmaceutical company inspired by the needs of people living with severe diseases and driven by science to make a meaningful difference in their lives. We combine our understanding of disease biology, scientific innovation and patient insights to develop differentiated medicines and solutions, with a focus on neurology, immunology and other areas of unmet medical need.

UCB 是一家全球性生物制药公司,深受严重疾病患者需求的启发,并以科学为驱动,致力于显著改善他们的生活。我们将对疾病生物学的理解、科学创新以及患者洞察相结合,开发具有差异化的药物和解决方案,重点聚焦于神经学、免疫学以及其他存在未满足医疗需求的领域。

Founded in Belgium in 1928, UCB has more than 10,000 employees in approximately 40 countries and generated revenue of €7.7 billion in 2025. UCB is listed on Euronext Brussels (symbol: UCB)..

UCB于1928年在比利时成立,在约40个国家拥有超过10,000名员工,2025年营收达77亿欧元。UCB在布鲁塞尔泛欧交易所上市(股票代码:UCB)。

About Biogen

关于百健

Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients’ lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes.

百健成立于1978年,是一家领先的生物技术公司,通过开创性的科学创新,提供变革患者生命的新药,并为股东和社区创造价值。我们运用对人类生物学的深刻理解,并利用不同技术平台,推进同类首创的治疗方案或疗法,以实现更优的临床结果。

Our approach is to take bold risks, balanced with return on investment to deliver long-term growth..

我们的方法是在投资回报的平衡下大胆承担风险,以实现长期增长。

We routinely post information that may be important to investors on our website at www.biogen.com. Follow us on social media – Facebook, LinkedIn, X, YouTube.

我们定期在公司网站 www.biogen.com 上发布可能对投资者具有重要意义的信息。请在社交媒体上关注我们——Facebook、LinkedIn、X 和 YouTube。

Forward-looking Statements - UCB

前瞻性声明 - UCB

This document contains forward-looking statements, including, without limitation, statements containing the words “potential”, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will”, “continue” and similar expressions. These forward-looking statements are based on current plans, estimates and beliefs of management.

本文件包含前瞻性陈述,包括但不限于含有“潜在”、“相信”、“预期”、“期望”、“打算”、“计划”、“寻求”、“估计”、“可能”、“将”、“继续”及类似表述的陈述。这些前瞻性陈述基于管理层当前的计划、估计和信念。

All statements, other than statements of historical facts, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, arbitration, political, regulatory or clinical results or practices and other such estimates and results.

除历史事实陈述外,所有陈述均可能被视为前瞻性陈述,包括对收入、营业利润率、资本支出、现金及其他财务信息的估计,以及对预期法律、仲裁、政治、监管或临床结果或实践的预测和其他此类估计与结果。

By their nature, such forward-looking statements are not guaranteeing future performance and are subject to known and unknown risks, uncertainties, and assumptions which might cause the actual results, financial condition, performance or achievements of UCB, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements contained in this document..

就其性质而言,此类前瞻性陈述并不保证未来表现,且受已知和未知的风险、不确定性和假设的影响,这些因素可能导致UCB的实际结果、财务状况、表现或成就,或行业结果,与本文件中所含前瞻性陈述所明示或暗示的任何未来结果、表现或成就存在重大差异。

Important factors that could result in such differences include but are not limited to: global spread and impacts of wars, pandemics and terrorism, the general geopolitical environment, climate change, changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms or within expected timing, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, safety, quality, data integrity or manufacturing issues, supply chain disruption and business continuity risks; potential or actual data security and data privacy breaches, or disruptions of UCB’s information technology systems, product liability claims, challenges to patent protection for products or product candidates, competition from other products including biosimilars or disruptive technologies/business models, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in laws and/or rules pertaining to tax and duties or the administration of such laws and/or rules, and hiring, retention and compliance of employees.

可能导致此类差异的重要因素包括但不限于:战争、流行病和恐怖主义的全球蔓延及其影响;总体地缘政治环境;气候变化;总体经济、商业和竞争状况的变化;无法获得必要的监管批准,或未能在可接受的条款下或预期的时间内获得此类批准;与研发相关的成本;优时比(UCB)管线中或正在开发的产品前景的变化;未来司法判决或政府调查的影响;安全、质量、数据完整性或生产问题;供应链中断和业务连续性风险;潜在或实际的数据安全和数据隐私泄露,或优时比信息技术系统的中断;产品责任索赔;对产品或候选产品的专利保护提出的挑战;来自其他产品(包括生物类似药)或颠覆性技术/商业模式竞争;法律或法规的变化;汇率波动;与税收和关税相关的法律和/或规则或其执行方面的变化或不确定性;以及员工的招聘、留任和合规问题。

There is no guarantee that new product candidates will be discovered or identified in the pipeline, or that new indications for existing products will be developed and approved. Movement from concept to commercial product is uncertain; preclinical results do not guarantee safety and efficacy of product candidates in humans.

无法保证能够发现或识别出新的候选产品,也无法保证现有产品的新的适应症将得到开发和批准。从概念到商业化产品的过程具有不确定性;临床前研究结果并不能保证候选产品在人体中的安全性和有效性。

So far, the complexity of the human body cannot be reproduced in computer models, cell culture systems or animal models. The length of the timing to complete clinical trials and to get regulatory approval for product marketing has.

迄今为止,计算机模型、细胞培养系统或动物模型尚无法重现人体的复杂性。完成临床试验并获得产品上市监管批准所需的时间长度也是如此。

Given these uncertainties, the public is cautioned not to place any undue reliance on such forward-looking statements. These forward-looking statements are made only as of the date of this document, and do not reflect any potential impacts from the evolving event or risk as mentioned above as well as any other adversity, unless indicated otherwise.

鉴于上述不确定性,谨提醒公众勿对前述前瞻性陈述产生不当依赖。除非另有说明,这些前瞻性陈述仅反映截至本文件发布之日的情况,并未体现上述不断演变的事件或风险以及其他不利因素可能产生的任何影响。

The company continues to follow the development diligently to assess the financial significance of these events, as the case may be, to UCB..

本公司继续密切关注事态发展,以评估这些事件对UCB的财务影响(如适用)。

UCB expressly disclaims any obligation to update any forward-looking statements in this document, either to confirm the actual results or to report or reflect any change in its forward-looking statements with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless such statement is required pursuant to applicable laws and regulations..

UCB 明确声明,除非适用法律和法规另有要求,否则其不承担任何义务以更新本文件中的任何前瞻性陈述,无论是为了确认实际结果,还是为了报告或反映其前瞻性陈述的任何变化,或反映任何此类陈述所依据的事件、条件或情况的任何变化。

Biogen Safe Harbor

渤健安全港声明

This news release contains forward-looking statements, including, among others, relating to: the potential benefits, safety and efficacy of dapirolizumab pegol (DZP); the potential of dapirolizumab pegol to address the needs of people living with systemic lupus erythematosus (SLE); the anticipated benefits, risks and potential of Biogen's collaboration arrangements with UCB; the potential of Biogen's commercial business and pipeline programs, including dapirolizumab pegol; potential regulatory discussions, submissions and approvals and the timing thereof; and the risks and uncertainties associated with drug development and commercialization.

本新闻稿包含前瞻性陈述,包括但不限于以下内容:达匹罗珠单抗聚乙二醇(DZP)的潜在益处、安全性和有效性;达匹罗珠单抗聚乙二醇满足系统性红斑狼疮(SLE)患者需求的潜力;Biogen与UCB合作安排的预期益处、风险和潜力;Biogen商业业务和管线项目(包括达匹罗珠单抗聚乙二醇)的潜力;潜在的监管讨论、提交和批准及其时间安排;以及与药物开发和商业化相关的风险和不确定性。

These forward-looking statements may be accompanied by such words as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “goal,” “guidance,” “hope,” “intend,” “may,” “objective,” “outlook,” “plan,” “possible,” “potential,” “predict,” “project,” “prospect,” “should,” “target,” “will,” “would,” and other words and terms of similar meaning.

这些前瞻性陈述可能伴随使用“旨在”、“预期”、“假设”、“相信”、“考虑”、“继续”、“可能”、“估计”、“期望”、“预测”、“目标”、“指引”、“希望”、“打算”、“可以”、“目的”、“展望”、“计划”、“有可能”、“潜在”、“预言”、“规划”、“前景”、“应该”、“指标”、“将”、“将会”等词语以及具有类似含义的其他字词和术语。

Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval.

药物开发和商业化涉及高度风险,只有少数研发项目最终实现产品的商业化。早期临床试验的结果可能无法反映完整结果或后期及更大规模临床试验的结果,也不能确保获得监管批准。

You should not place undue reliance on these statements. Given their forward-looking nature, these statements involve substantial risks and uncertainties that may be based on inaccurate assumptions and could cause actual results to differ materially from those reflected in such statements..

您不应过度依赖这些陈述。鉴于其前瞻性性质,这些陈述涉及重大风险和不确定性,可能基于不准确的假设,并可能导致实际结果与这些陈述所反映的情况存在重大差异。

These forward-looking statements are based on management's current beliefs and assumptions and on information currently available to management. Given their nature, we cannot assure that any outcome expressed in these forward-looking statements will be realized in whole or in part. We caution that these statements are subject to risks and uncertainties, many of which are outside of our control and could cause future events or results to be materially different from those stated or implied in this document, including, among others, factors relating to: uncertainty of our long-term success in developing, licensing, or acquiring other product candidates or additional indications for existing products; expectations, plans, prospects and timing of actions relating to product approvals, approvals of additional indications for our existing products, sales, pricing, growth, reimbursement and launch of our marketed and pipeline products; the potential impact of increased product competition in the biopharmaceutical and healthcare industry, as well as any other markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways; our ability to effectively implement our corporate strategy; difficulties in obtaining and maintaining adequate coverage, pricing, and reimbursement for our products; the drivers for growing our business, including our dependence on collaborators and other third parties for the development, regulatory approval, and commercialization of products and other aspects of our business, which are outside of our full control; risks related to commercialization of biosimilars, which is subject to such risks related to our relia.

这些前瞻性陈述基于管理层当前的信念和假设以及管理层目前可获得的信息。鉴于其性质,我们无法保证这些前瞻性陈述中表达的任何结果将全部或部分实现。我们提醒,这些陈述受风险和不确定性的影响,其中许多超出我们的控制范围,并可能导致未来事件或结果与本文件中陈述或暗示的内容存在重大差异,包括但不限于以下相关因素:我们在开发、许可或收购其他候选产品或现有产品的额外适应症方面长期成功的不确定性;与产品批准、现有产品额外适应症的批准、销售、定价、增长、报销以及已上市产品和在研产品的推出相关的期望、计划、前景和行动时机;生物制药和医疗保健行业以及我们参与竞争的任何其他市场中产品竞争加剧的潜在影响,包括来自新原研疗法、仿制药、前药和现有产品的生物类似药以及通过简化监管途径批准的产品的竞争加剧;我们有效实施公司战略的能力;在获得和维持我们产品的充分覆盖、定价和报销方面遇到的困难;推动我们业务增长的因素,包括我们在产品开发、监管批准和商业化以及其他业务方面对合作者和其他第三方的依赖,而这些方面不完全处于我们的控制之下;与生物类似药商业化相关的风险,其中包括与我们可靠性相关的风险。

These statements speak only as of the date of this presentation and the discussions during this conference call and are based on information and estimates available to us at this time. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected.

这些陈述仅反映本演示文稿及本次电话会议讨论之日的情况,并基于我们目前可获得的信息和估计。如果已知或未知的风险或不确定性成为现实,或者基本假设被证明不准确,实际结果可能与过往结果以及预期、估计或预测的结果存在重大差异。

Investors are cautioned not to put undue reliance on forward-looking statements. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and in our subsequent reports on Form 10-Q. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements whether as a result of any new information, future events, changed circumstances or otherwise..

提醒投资者不要过度依赖前瞻性陈述。有关风险、不确定性及其他事项的进一步列表和说明,请参阅我们截至2025年12月31日财政年度的10-K表格年度报告以及后续的10-Q表格报告。除非法律另有要求,我们不承担任何义务公开更新任何前瞻性陈述,无论是由于新信息、未来事件、情况变化或其他原因。

Biogen Digital Media Disclosure

渤健数字媒体披露

We use, and expect in the future to use, our investor relations website (investors.biogen.com), the Biogen LinkedIn account (linkedin.com/company/biogen-) and the Biogen X account (https://x.com/biogen) as a means of disclosing material nonpublic information to the public in a broad, non-exclusionary manner, including for purposes of complying with our obligations under the SEC's Regulation Fair Disclosure (Reg FD).

我们使用并预计未来将继续使用我们的投资者关系网站(investors.biogen.com)、Biogen 的 LinkedIn 账户(linkedin.com/company/biogen-)以及 Biogen 的 X 账户(https://x.com/biogen),作为以广泛且非排他性的方式向公众披露重大非公开信息的手段,包括为履行我们在美国证券交易委员会《公平披露条例》(Reg FD)下的义务。

Accordingly, investors should monitor our investor relations website and these social media channels in addition to our press releases, SEC filings, public conference calls and websites, as the information posted on them could be material to investors..

因此,投资者除了关注我们的新闻稿、美国证券交易委员会(SEC)文件、公开电话会议和网站外,还应监控我们的投资者关系网站及这些社交媒体渠道,因为发布在这些平台上的信息可能对投资者具有重大影响。

UCB Media Contact

UCB 媒体联系人

Adriaan Snauwaert

阿德里安·斯瑙瓦特

+32 497 70 23 46

+32 497 70 23 46

adriaan.snauwaert@ucb.com

adriaan.snauwaert@ucb.com

UCB Investor Contact

UCB 投资者联系

Yvonne Naughton

伊冯·诺顿

+44 175 344 7521

+44 175 344 7521

yvonne.naughton@ucb.com

yvonne.naughton@ucb.com

UCB Corporate Communications

UCB 企业传播部

Laurent Schots

洛朗·肖茨

+32 255 992 64

+32 255 992 64

laurent.schots@ucb.com

laurent.schots@ucb.com

Biogen Media Contact

渤健媒体联系人

Madeleine Shin

玛德琳·辛

+1 781 464 3260

+1 781 464 3260

public.affairs@biogen.com

public.affairs@biogen.com

Biogen Investor Contact

Biogen 投资者联系

Tim Power

蒂姆·鲍尔

+1 781 464 2442

+1 781 464 2442

IR@biogen.com

IR@biogen.com

References:

参考文献:

Aranow C, Kalunian KC, Arnaud L, et al. Treatment response measure for systemic lupus erythematosus (TRM-SLE): application to a phase 3 trial of dapirolizumab pegol.

Aranow C, Kalunian KC, Arnaud L, 等. 系统性红斑狼疮治疗反应评估指标(TRM-SLE):在达匹罗珠单抗聚乙二醇化制剂III期临床试验中的应用。

Arthritis Rheumatol

《关节炎与风湿病》

. 2026;78(suppl 9):Abstract 1296.

. 2026;78(增刊9):摘要1296。

Connelly K, Eades LE, Koelmeyer RL, et al. Towards a novel clinical outcome assessment for systemic lupus erythematosus: first outcomes of an international taskforce.

康奈利 K,伊德斯 LE,科尔迈耶 RL,等。迈向系统性红斑狼疮的新型临床结局评估:国际任务组的初步成果。

Nat Rev Rheumatol

《自然综述·风湿病学》

. 2023;19(9):592–602. doi:10.1038/s41584-023-00993-7.

. 2023;19(9):592–602. doi:10.1038/s41584-023-00993-7.

Connelly K, Koelmeyer R, Ayton D, et al. Domains for inclusion in a novel Treatment Response Measure for Systemic Lupus Erythematosus (TRM-SLE): results of a modified Delphi study.

康奈利 K,科尔迈耶 R,艾顿 D,等。纳入系统性红斑狼疮新型治疗反应评估指标(TRM-SLE)的领域:一项改良德尔菲研究的结果。

Lupus Sci Med

狼疮科学与医学

. 2025;12(1):e001484. doi:10.1136/lupus-2024-001484.

. 2025;12(1):e001484. doi:10.1136/lupus-2024-001484.

Clowse MEB, Isenberg DA, Merrill JT, et al. Efficacy and safety of the CD40 ligand inhibitor dapirolizumab pegol in systemic lupus erythematosus (PHOENYCS GO): a randomised, double-blind, placebo-controlled, phase 3 trial.

Clowse MEB,Isenberg DA,Merrill JT,等。CD40配体抑制剂dapirolizumab pegol在系统性红斑狼疮中的疗效和安全性(PHOENYCS GO):一项随机、双盲、安慰剂对照的3期试验。

Lancet

柳叶刀

. Published online May 29, 2026. doi:10.1016/S0140-6736(26)00691-4.

在线发表于2026年5月29日。doi:10.1016/S0140-6736(26)00691-4。

Morand EF, Carter LM, Dall'Era M, et al. Dapirolizumab pegol treatment resulted in sustained attainment of low disease activity and remission in patients with systemic lupus erythematosus: 48-week results from a phase 3 trial.

Morand EF、Carter LM、Dall'Era M 等。达匹罗珠单抗聚乙二醇治疗使系统性红斑狼疮患者持续达到低疾病活动度和缓解状态:一项 III 期试验的 48 周结果。

Arthritis Rheumatol

关节炎与风湿病学

. 2026;78(suppl 9):Abstract 2196.

. 2026;78(增刊9):摘要2196。

Furie RA, Bruce IN, Dörner T, et al. Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus.

Furie RA, Bruce IN, Dörner T 等。达匹罗珠单抗聚乙二醇在中度至重度活动性系统性红斑狼疮患者中的二期、随机、安慰剂对照试验。

Rheumatology (Oxford)

风湿病学(牛津)

. 2021;60(11):5397–407.

. 2021;60(11):5397–407.

ClinicalTrials.gov. NCT04294667. https://clinicaltrials.gov/study/NCT04294667. Accessed November 6, 2026.

ClinicalTrials.gov. NCT04294667. https://clinicaltrials.gov/study/NCT04294667. 访问日期:2026年11月6日。

ClinicalTrials.gov. NCT06617325. https://clinicaltrials.gov/study/NCT06617325. Accessed November 6, 2026.

ClinicalTrials.gov. NCT06617325. https://clinicaltrials.gov/study/NCT06617325. 访问日期:2026年11月6日。